, inhibit mitochondrial function 2, 3 and induce changes in mammalian metabolic pathways 4 . There is a critical need to better understand the host effects of commonly used antibiotics.
Here, we have found that topical delivery of aminoglycoside antibiotics induces significant alteration of host gene expression, increasing the expression of antiviral interferon-stimulated genes (ISGs). Aminoglycoside-mediated ISG induction resulted in significant protection against RNA and DNA viruses and was independent of the host microbiota. ISG expression was dependent on Toll-like receptor 3 (TLR3) and the downstream signalling pathway, and robust recruitment of TLR3-expressing XCR1 + dendritic cells (DCs) to the vaginal mucosa. Our results reveal an unexpected induction of an antiviral state by commonly used aminoglycoside antibiotics.
To investigate the effect of local, vaginal, antibiotic treatment on genital herpes virus infection, we treated mice daily with an antibiotic cocktail (composed of 0.5 mg each of ampicillin, neomycin and vancomycin and 0.012 mg metronidazole) administered intravaginally. All mice were first injected subcutaneously with medroxyprogesterone acetate (Depo-Provera) to synchronize oestrus cycles and increase herpes simplex virus type 2 (HSV-2) infectivity 5 . After a week of daily antibiotic treatment, mice were infected intravaginally with HSV-2. After genital infection, HSV-2 undergoes multiple rounds of local replication in the vaginal mucosa, which can be quantified by plaque assays for infectious virus in the vaginal wash 6, 7 . In mice, by four days post infection, the virus travels to the dorsal root ganglion where it can spread to fresh epithelial sites, resulting in disease symptoms including hair loss and hind-limb paralysis, which can be quantified using a clinical scoring system 8 . Neural spread of HSV-2 is required for disease, as herpesviruses unable to replicate in neurons are unable to cause neurological symptoms and morbidity 9 . Antibiotic-treated mice had significantly decreased vaginal viral titres and displayed fewer clinical symptoms of genital herpes infection, indicating suppression of both early and late stages of HSV-2 infection (Fig. 1a,b) . Vaginal viral titres of antibioticpretreated mice were only suppressed early in infection (days 1-3), eventually reaching levels similar to control mice ( Supplementary  Fig. 1a ). Reduced viral titres were also observed in the dorsal root ganglion following antibiotic treatment ( Supplementary Fig. 1c ). Importantly, this transient suppression was sufficient to significantly protect mice against morbidity as antibiotic-pretreated mice displayed little to no disease pathology (Fig. 1a) .
To determine which of the antibiotics in the cocktail are required for protection against HSV infection, we treated mice singly with each antibiotic. We excluded metronidazole as it was present in very low quantities in the cocktail. Of the four antibiotics tested, neomycin alone recapitulated the host protection observed with the full antibiotic cocktail, with disease scores (Fig. 1c) and vaginal viral titres ( Fig. 1d and Supplementary Fig. 1b ) significantly lower than both PBS controls and the other single-antibiotic-treated mice (Fig. 1c) . Thus, neomycin is the antiviral ingredient in the antibiotic cocktail.
Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner
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Antibiotic-mediated effects on host immunity are often attributed to reduction or dysbiosis of relevant commensal bacterial communities. To determine if the neomycin-mediated antiviral effect requires the host microbiota, we treated germ-free mice intravaginally with neomycin. Notably, neomycin treatment of germ-free hosts also resulted in significant protection against genital HSV-2 infection. Neomycin-treated germ-free mice displayed no viral disease pathology ( Fig. 1e ) and had no detectable replicating virus in the vaginal mucosa (Fig. 1f) indicating that the neomycin-mediated antiviral effect is independent of live or dead vaginal commensals, or microbiota in general. To determine if neomycin treatment had a therapeutic effect, HSV-2 infected mice were treated with neomycin at 4, 24,48 and 72 h post infection. Post-exposure neomycin treatment resulted in lower viral titres ( Fig. 1h and Supplementary  Fig. 1d ) and reduced disease scores (Fig. 1g) . Post-exposure neomycin starting at 24 h post infection resulted in variable protection ( Supplementary Fig. 1e,f) . These data indicate that vaginal application of neomycin before or shortly after exposure reduces HSV-2 infection and disease, independent of commensal bacteria.
To elucidate the mechanisms underlying neomycin-mediated host resistance against HSV-2, we analysed vaginal gene transcription prior to infection. We identified over a hundred significantly upregulated genes ( Fig. 2a and Supplementary Table 1) . No genes were significantly downregulated in expression. Using Ingenuity pathway analysis, we found that genes in the type I interferon (IFN) pathway were heavily enriched (Fig. 2b) , with over 30% of the upregulated genes falling within this pathway. We independently confirmed the upregulation of a subset of IFN-stimulated-genes (ISGs) using quantitative PCR (Fig. 2c) . ISG expression was also increased in germ-free mice upon neomycin treatment ( Supplementary Fig. 2 ). Neomycin-induced ISG expression was rapid, as a single treatment was sufficient to significantly increase ISG expression 2-5-fold, although not to the levels observed after a week's treatment (8-10-fold) ( Supplementary Fig. 3a) . Neomycin-mediated ISG induction was and germ-free (e,f) mice were treated subcutaneously with medroxyprogesterone acetate (Depo-Provera) and 5 days later were inoculated intravaginally with an antibiotic cocktail (ABX) (a,b) or singly with the indicated antibiotics (c-f) daily for 6 days (n = 5 mice per group). After 6 days of treatment, all mice were infected intravaginally with HSV-2. For post-exposure neomycin treatment, Depo-treated mice (n = 9-10, data pooled from two independent experiments) were infected with HSV-2, then treated with 1 mg neomycin or PBS at 4, 24, 48 and 72 h after infection (g,h). For all infected mice, disease score was monitored daily (a,c,e,g) and vaginal wash was collected on the first three days (b,d,f,h). All error bars represent standard error of the mean (s.e.m.). Significance was calculated using two-way analysis of variance (ANOVA) with Holm-Sidak correction for multiple comparisons (a,c,e,g) or with Fisher's least significant difference (LSD) test (b,d,f,h). *P values < 0.05. Exact P values are reported in Supplementary Table 2 . Experiments in a, b, g and h were repeated independently with similar results. p.f.u., plaque-forming unit; h.p.i., hours post infection.
also dependent on dose, as increased amounts of neomycin correspondingly increased ISG expression ( Supplementary Fig. 3a ). Significant ISG induction was maintained up to 3 days after neomycin treatment and was only partially lost at 1 week, with five of eight genes still significantly upregulated ( Supplementary Fig. 3c ).
Finally, neomycin-mediated ISG induction was restricted to the site of application, as we observed no upregulation of ISG expression in the lungs of neomycin-treated mice ( Supplementary Fig. 3d ).
Neomycin is a member of a large and diverse group of aminoglycosides, many of which are commonly used to treat bacterial Significantly differentially expressed known genes (fold expression > 2× , P < 0.05) are labelled. b, Ingenuity pathway analysis was used to identify the top ten signalling pathways enriched upon neomycin treatment. PRRs, pattern recognition receptors. c, In an independent experiment, Depotreated mice were treated with neomycin or PBS for 6 days (n = 9, data pooled from two independent experiments) and vaginal gene expression was measured by qPCR. Error bars represent s.e.m. WT, wild type. d, Depo-treated mice were inoculated intravaginally with the indicated aminoglycosides (1 mg per day) for 2 days (n = 3-6 mice per group, data pooled from two independent experiments). Vaginal gene expression was analysed by qPCR, and all comparisons were made against PBS samples. Error bars represent standard deviation (s.d.). In c and d, statistical significance of gene expression data was calculated using unpaired t-tests with Holm-Sidak correction for multiple comparisons. *P < 0.05. e,f, Depo-treated mice (n = 3-12, data pooled from three independent experiments) were treated intravaginally with 1 mg of the indicated aminoglycosides daily for 6 days and then infected with HSV-2. Disease score was monitored (e) and vaginal viral titres measured (f). Error bars represent s.e.m. and statistical significance was calculated using two-way ANOVA with Holm-Sidak correction for multiple comparisons. Exact P values for all comparisons are reported in Supplementary Table 2 .
infection. To determine if ISG induction was common across the aminoglycoside family, we treated mice with a panel of structurally diverse aminoglycosides for 1-2 days. Five of the seven aminoglycosides we tested increased ISG expression to varying levels of significance upon application to the vaginal mucosa (Fig. 2d) . The two non-inducers were streptomycin, which contains a streptamine core distinct from the other 2-deoxystreptamine-containing aminoglycosides, and amikacin, a kanamycin homologue that contains an addition l-haba side chain 10 . Thus, the majority of the aminoglycosides tested induce ISG expression on application to the vaginal mucosa. Because aminoglycosides mediate their antibiotic activity by binding ribosomal RNA, we tested if this ISG induction was observed in other ribosome-targeting antibiotics 11 . Mice were treated intravaginally with tetracycline or chloramphenicol, compounds that inhibit bacterial protein synthesis by binding the 30S and 50S ribosome subunit, respectively 11 ( Supplementary Fig. 4a,b) . Neither compound induced high levels of ISGs, suggesting that ISG induction is not a common property of antibiotics that target the ribosome. Previous studies have reported increased mitochondrial dysfunction and a loss of mitochondria in mammalian cells 2, 12 on treatment with multiple classes of antibiotics. We observed no reduction in total mitochondrial DNA in neomycin-treated vaginal tissues ( Supplementary Fig. 4c ).
To determine the link between ISG expression and antiviral protection, we compared the ability of ISG-inducing and ISG noninducing aminoglycosides to protect mice against HSV-2 infection. We selected two ISG-inducing aminoglycosides (kasugamycin and sisomicin) as well as the two ISG non-inducing aminoglycosides (amikacin and streptomycin). Mice pretreated with ISG noninducers were not protected against HSV-2 infection (Fig. 2e,f) . Kasugamycin and sisomicin treatment, however, resulted in significant reduction in vaginal viral titres and disease scores, displaying equivalent levels of antiviral protection to neomycin (Fig. 2e,f) . These data indicated that ISG induction by aminoglycosides corresponds to their ability to protect mice against viral challenge.
Next, we examined if aminoglycoside induction of antiviral immunity was specific to the vaginal tract or if similar protection could be observed in other mucosal surfaces such as the respiratory tract. A single intranasal dose of neomycin sufficed to significantly upregulate ISG expression in the lung (Fig. 3a) . To determine if this ISG induction was functional, we used an Mx1 congenic mouse model of influenza infection 13 . Many inbred mouse strains, including C57BL/6, lack Mx1 (ref. 14 ). Mx1 encodes myxovirus resistance protein 1, a dynamin-like GTPase that blocks primary transcription of influenza by binding to viral nucleoproteins 15 . Mx1 is also an ISG and is induced by neomycin treatment (Fig. 3a) . In mice lacking Mx1, innate resistance to influenza is abrogated, and they rely on adaptive immunity. We previously showed that oral neomycin treatment renders Mx1-deficient mice susceptible to influenza disease because it depletes the gut commensal bacteria that normally activate DCs that prime CD8 T cells 16 . In contrast, the use of Mx1 congenic mice allows us to study the ability of intranasal neomycin to elicit innate antiviral resistance through induction of ISGs including Mx1. We infected neomycin-pretreated Mx1 congenic mice with a highly virulent influenza A virus A/PR8 (hvPR8), which was selected for its ability to replicate rapidly even in the presence of Mx1 (ref. 17 ). A single dose of neomycin was sufficient to significantly increase survival following challenge with an otherwise lethal dose of hvPR8, with 40% of mice protected (Fig. 3b ). Intranasal treatment with the ISG non-inducer streptomycin failed to induce ISG expression in the lung (Fig. 3a) and Mx1 congenic mice pretreated with streptomycin were not protected against influenza infection (Fig.3b) .
We also tested the ability of aminoglycosides to protect against another RNA virus infection-Zika virus (ZIKV). ZIKV replicates in the vagina of wild-type (WT) mice and is controlled by interferon regulatory factor 3 (IRF3)-and IRF7-dependent type I IFN secretion and type I IFN receptor (IFNAR) signalling 18 . Given the ability of aminoglycosides to induce ISGs, we examined if aminoglycosidetreated hosts are protected against ZIKV infection. We found that kasugamycin and neomycin treatment resulted in significantly lower levels of ZIKV RNA in the vaginal mucosa 1-2 days post infection (Fig. 3c) . Although vaginal ZIKV titres in neomycin-treated mice reached those in PBS-treated controls by day 3 post infection, ZIKV replication in kasugamycin-treated mice remained significantly lower in a large proportion of mice in this group (Fig. 3c) .
To extend our findings to human cells, we treated primary peripheral blood monocytes obtained from healthy donors with kasugamycin. Kasugamycin treatment significantly increased ISG expression in human monocytes, similar to Poly(I:C) treatment (Fig. 3d) . Six hours of kasugamycin treatment was sufficient to induce robust ISG expression and significantly reduce replication of influenza A virus in monocytes (Fig. 3e) . Collectively, our results demonstrate that aminoglycosides provide antiviral protection against a diverse set of DNA and RNA viruses: HSV-2, influenza A virus and ZIKV.
Because neomycin treatment resulted in increased expression of genes in nucleic acid sensing pathways, we asked if cytosolic or endosomal nucleic acid sensors were involved. To test the requirement of cytosolic nucleic acid sensors, mice lacking the RIG-I like receptor signalling adaptor Mavs, or the cytosolic DNA sensor cGAS (Mb21d1), and its downstream adapter STING (Tmem173) were treated with neomycin or PBS, and subsequent vaginal gene expression was examined. Although neomycin induction of ISG expression was intact in cGAS Fig. 5e ,f). These results indicate that the cytosolic DNA sensor signalling pathway is dispensable for ISG induction by neomycin, while RNA sensor signalling pathways play a partial role in aminoglycoside-mediated ISG induction.
We next investigated the role of endosomal RNA sensors. TLR7 signalling was dispensable for aminoglycoside-mediated antiviral protection ( Supplementary Fig. 6a,b) . However, we found that treatment of Tlr3 −/− mice with neomycin resulted in no ISG induction ( Fig. 4a) and was accompanied by significant loss of protection against HSV-2 infection (Fig. 4b,c) . TLR3 signals via the adaptor protein Toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF) 19 . To confirm activation of the TLR3 signalling pathway in aminoglycoside-mediated antiviral protection, we treated Trif −/− mice with neomycin. ISG induction was diminished in Trif −/− mice as compared to neomycin-treated WT mice (Fig. 4d ).
Similar to Tlr3
−/− hosts, we observed a lack of protection against genital HSV-2 infection. Neomycin-treated Trif −/− mice had equivalent vaginal viral titres and similar disease scores as PBS controls (Fig. 4e,f) . Finally, we investigated the role of transcription factors downstream of TLR3 and TRIF signalling. ISGs downstream of cytosolic and endosomal nucleic acid sensors require IRF3 and IRF7 for induction 20 , so we investigated neomycin-mediated ISG expression in Irf3 −/− Irf7 −/− mice. Similar to Trif −/− and Tlr3 −/− mice, no upregulation of ISGs was observed in neomycin-treated Irf3 −/− Irf7 −/− mice ( Fig. 4g) , and this lack of ISG induction correlated with the lack of protection against HSV-2 infection (Fig. 4h,i) . Induction of ISGs via IRF3 and IRF7 often requires signalling through IFNAR 21 but IFNindependent ISG induction has also been reported 22 .
Neomycinmediated ISG induction was intact in Ifnar1
−/− mice, suggesting that IFNAR signalling is dispensable (Supplementary Fig. 7a ). However,
NATuRe MICRobIoloGy because basal ISG expression was much lower in Ifnar1
−/− mice, neomycin treatment only increased gene expression compared to those of untreated WT mice and thus neomycin treatment was not accompanied by significant antiviral protection ( Supplementary  Fig. 7b,c) . Collectively, our results suggest that neomycin induces ISG expression via activation of the TLR3-TRIF-IRF3/7 signalling pathway to confer protection against HSV-2.
We next examined the cell types responsible for ISG induction and antiviral protection in the vaginal mucosa upon neomycin treatment. The vaginal mucosa is composed of stratified squamous epithelial cells, small numbers of resident leukocytes and circulating leukocytes. We investigated whether ISG induction by neomycin requires tissue-resident cells or circulating leukocytes. To determine if circulating leukocytes were responsible for increased ISG expression, we blocked cellular recruitment by treating mice intravaginally with pertussis toxin (PTX). PTX blocks Gi-protein coupled receptor signaling, thereby preventing most chemokine-mediated cellular recruitment to the vaginal mucosa when applied intravaginally 23 . Treatment with PTX ablated the protective effect of neomycin as mice treated with both pertussis toxin and neomycin prior to infection had significantly reduced vaginal ISG expression compared to PTXuntreated mice (Fig. 5a ). This absence of ISG expression resulted in significantly higher levels of vaginal viral titers and an increase in disease pathology upon HSV-2 infection (Fig. 5b,c) . These results suggested that cellular recruitment to the vagina is a prerequisite for enhanced ISG induction and protection against HSV-2 conferred by topical neomycin treatment.
To determine the specific cell types recruited to the vaginal mucosa by neomycin, we compared the cellular composition of the vaginal mucosa in mice treated with neomycin and those treated with neomycin and PTX. Monocytes (CD11b
) and classical DCs (cDCs) (CD11c + ) were significantly increased upon neomycin treatment (Fig. 5d,e) . However, PTX treatment of neomycin-inoculated mice resulted in significant blockade of CD11c + and CD11b + CD11c + cells (Fig. 5e ), suggesting that one or both of these cell types might be responsible for the neomycin-mediated ISG induction.
To test this hypothesis, we isolated CD11c + cells from the vaginal tissue of neomycin-treated and control mice and found significant increases in transcripts of ISGs ( Supplementary Fig. 8 ). Similarly, these recruited CD11c + cells were also found to express IFN-β , unlike plasmacytoid DCs ( Supplementary Fig. 9a-c) . To determine whether DCs are required for the increase in ISG expression following neomycin application, we treated CD11cDTR (diphtheria toxin receptor) mice with diphtheria toxin to deplete DCs and then administered neomycin intravaginally. In the absence of DCs, neomycin treatment failed to increase vaginal ISG expression (Fig. 5f) . Collectively, our results suggest that recruited DCs are necessary for aminoglycoside-mediated ISG expression. 
Hours post infection Fig. 3 | Aminoglycosides confer broad protection against both RNA and DNA viruses. a, Mice were treated intranasally with 2 mg neomycin or streptomycin (data pooled from two independent experiments, one with PBS and neomycin groups (n = 4) and the second with PBS, neomycin and streptomycin treatment groups (n = 3)) and gene expression analysed 24 h later in lung tissue. Error bars represent s.d. and significance was calculated using multiple t-tests with Holm-Sidak correction for multiple comparisons. b, Mx1 congenic mice (data pooled from two independent experiments, one with PBS and neomycin groups (n = 4) and the second with PBS, neomycin and streptomycin treatment groups (n = 5)) were pretreated intranasally with the indicated aminoglycoside (2 mg) or PBS and infected 24 h later with highly virulent influenza strain PR8, and survival curves were compared using a log-rank (Mantel-Cox) test. c, Depo-treated mice (n = 7-8, data pooled from two independent experiments) received intravaginal aminoglycoside or PBS daily for 6 days and were infected with 25,000 p.f.u. Zika virus (ZIKV) intravaginally, and vaginal viral titres were calculated by qPCR. Error bars represent s.e.m. and significance was calculated using two-way ANOVA with Fisher's LSD test. d, Primary human monocytes were treated with kasugamycin (2 mg ml ). Six hours after treatment, gene expression was analysed (n = 3 replicates per treatment). Error bars represent s.d. and significance was calculated using multiple t-tests with Holm-Sidak correction for multiple comparisons. e, In a separate experiment, kasugamycintreated monocytes were infected with influenza A/PR/8/34 (H1N1) strain at a multiplicity of infection of 2 and RNA collected 2 and 6 h post infection (n = 3 replicates per treatment). Virus levels were quantified by qPCR using primers against polymerase A. Error bars represent s.d. and significance was calculated using two-way ANOVA with Fisher's LSD test. *P < 0.05. Exact P values are reported in Supplementary Table 2 . Experiments shown in d and e were repeated independently with similar results.
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Because both monocyte-derived and classical DCs (cDCs) are recruited to the vaginal mucosa, we wondered if TLR3 expression could be used to identify the specific DC subset involved. It is well known that TLR3 is expressed selectively by the cDC1 and not cDC2 subsets 24, 25 . Examining TLR3 expression across all DC subsets using the RNA sequencing data sets deposited in the Immunological Genome project 26 confirmed a single cDC subset with high levels of TLR3 expression: CD8α + DCs (cDC1) from the thymus and spleen (Supplementary Fig. 10 ). In non-lymphoid tissue, these cells are characterized as CD103 + DCs, and both subsets express high levels of TLR3 (ref. 27 ). Recent studies have identified XCR1 as a defining cell surface marker for the cDC1 subset 28 . We therefore measured the recruitment of XCR +
CD103
+ DCs in the vaginal mucosa. Neomycin treatment resulted in significant recruitment of CD103 +
XCR1
+ DCs, which was blocked with co-treatment with pertussis toxin (Fig. 6a,b) . To determine if this was the DC subtype responsible for ISG induction by aminoglycosides, we depleted mice of XCR1 + DCs 29 before intravaginal aminoglycoside treatment.
Mice lacking XCR1
+ DCs showed no induction of ISG expression following aminoglycoside treatment (Fig. 6c) . These data suggest that mucosal application of aminoglycosides induce ISGs in a TLR3 and XCR1
+ DC-dependent manner to confer antiviral protection. Systemic administration of aminoglycosides has known toxic side effects, including ototoxicity and nephrotoxicity 30 . Aminoglycoside compounds can accumulate in the sensory hair cells of the inner ear causing caspase-mediated cell death, which results in irreversible hearing loss [31] [32] [33] . Although nephrotoxicity can be reversible, significant necrosis can occur, resulting in kidney dysfunction 34, 35 . However, we observed no toxicity in mice treated with intravaginal aminoglycosides. To determine if intravaginal aminoglycoside treatment resulted in mucosal toxicity, we conducted blinded histological analysis of aminoglycoside-treated and control vaginal tissues, which found no histopathological differences between the two groups ( Supplementary Fig. 11a) . Similarly, ex vivo treatment of splenocytes with aminoglycosides induced robust ISG expression with little accompanying toxicity ( Supplementary Fig. 11b-d) . Similar to our in vivo results, depletion of DCs resulted in significant loss of ISG induction (Supplementary Fig. 11e) .
Aminoglycosides act by binding bacterial ribosomal RNA, but they also bind mitochondrial and mammalian ribosomal RNA [36] [37] [38] . 
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Our data show that aminoglycoside induction of ISG requires TLR3, which is a sensor of dsRNA. We hypothesized that aminoglycosides may induce ISG expression by rendering host RNA more 'visible' to TLR3 in neighbouring DCs. To test this, we first treated splenocytes with kasugamycin and washed the cells multiple times to remove extracellular aminoglycosides. Next, we incubated these kasugamycin-treated cells with splenic DCs that include XCR1 + DCs from WT and TLR3 knockout mice and measured DC-specific ISG expression. Incubation with kasugamycin-treated splenocytes was sufficient to increase ISG expression in WT but not Tlr3 −/− DCs ( Supplementary Fig. 12 ).
These data suggest that aminoglycosides may bind to host RNA and render it more potent for TLR3 activation. To test this, we treated splenocytes with a combination of aminoglycosides and dsRNA Poly(I:C). We found that a 1:1,000 ratio of Poly(I:C) to kasugamycin significantly induced ISG expression at greater levels than either compound alone (Supplementary Fig. 13 ). This enhancement was dependent on both TLR3 and TRIF signalling ( Supplementary  Fig. 13 ). Collectively, these data indicate that at high molar ratios, kasugamicin synergizes with dsRNA to stimulate TLR3.
Our data show an unexpected antiviral effect of aminoglycosides in mucosal tissues. Vaginal application of aminoglycosides conferred resistance against both DNA and RNA viruses. Surprisingly, aminoglycoside-mediated antiviral protection occurred in germfree mice, indicating a microbiome-independent mechanism of resistance. Mucosal aminoglycoside treatment recruited XCR1 + DCs, and induced ISG expression via TLR3, TRIF and transcription factors IRF3 and IRF7. Finally, this antiviral protection could be extended to both the nasal mucosa and primary human monocytes.
Other antibiotic compounds have been reported previously to inhibit viral replication. Several screens of bioactive compounds for antiviral activity have identified antibiotic compounds including azithromycin and nanchangmycin 39, 40 . Azithromycin, a macrolide antibiotic, potently inhibits ZIKV replication in cell culture via an 
Gr1
− and MHC-II + (d) and quantified (e) (gating schema are provided in Supplementary Fig. 14) . Error bars represent s.d. and significance was calculated using two-way ANOVA with Fisher's LSD test. Experiments shown in d and e were repeated independently with similar results. f, Depo-Provera-treated CD11cDTR mice were treated with 125 ng diphtheria toxin to deplete DCs, treated intravaginally with 1 mg neomycin for 2 days (n = 8, data pooled from two independent experiments) and vaginal gene expression was measured by qPCR. Error bars represent s.e.m. Significance was calculated using unpaired ttests, correcting for multiple comparisons. *P < 0.05. Exact P values for all comparisons are reported in Supplementary Table 2 .
NATuRe MICRobIoloGy as yet unknown mechanism 40 . Pretreatment of cells with nanchangmycin blocks entry of many flaviviruses including dengue virus and chikungunya virus by inhibiting clathrin-mediated endocytosis 39 . These studies collectively highlight the unexpected antiviral functions of antibiotics, albeit through distinct downstream pathways. Our study identifies a class of antibiotics, aminoglycosides, which mediate their antiviral activity by increasing host expression of a broad range of ISGs, potentially reducing the opportunity for viruses to develop resistance. Of note, a previous study demonstrated that macrolide antibiotics induced type I and III IFNs in epithelial cells 41 . Another study showed the ability of anthracyclines (chemotherapy agents that are natural products of Streptomyces bacteria) to also induce ISG expression in cancer cells in a TLR3-dependent manner 42 . Thus, bacterial products with nucleic acid binding capacity may have the ability to trigger TLR3 and possibly other PRRs. Because aminoglycoside-mediated antiviral activity was suppressed at higher levels in Trif −/− hosts as compared to Tlr3 −/− hosts, it is possible that an alternative sensor upstream of TRIF, such as TLR4, may also play a role.
How do aminoglycosides induce ISGs? Our results indicate that aminoglycoside treatment in the vaginal mucosa increases expression of chemokines and is accompanied by recruitment of monocyte-derived DCs and cDCs. Blocking this recruitment through PTX treatment, or depletion of DCs, aborted the ISG response. With TLR3 as the key sensor required for ISGs and as only cDC1s express TLR3 (ref. 27 ), we further determined that XCR1 + cDC1s were required for ISG induction in the vaginal mucosa.
Aminoglycosides could be taken up by these DCs via endocytosis 43 or through the Transient receptor potential cation channel, subfamily V (TRPV) family of ion channels 44 , which are also expressed on DCs 45 . Aminoglycosides may also be taken up by the vaginal epithelial cells via the megalin receptor which has been shown to bind these compounds 46, 47 . Aminoglycosides are known for inducing cytotoxicity in specific cell types such as the hair cells of the inner ear and kidney epithelial cells 30, 31, 34 , but their effect on immune cells has not been well characterized. We observed no inflammation or cytotoxicity in aminoglycoside-treated vaginal tissues ( Supplementary  Fig. 11a ). Of note, incubation of DCs with kasugamycin-treated splenocytes was sufficient to induce ISG expression albeit at lower levels than direct aminoglycoside treatment (Supplementary Fig. 12 ). As XCR1 + DCs are known for their cross-presentation of antigens associated with dead or dying cells 48, 49 , it is conceivable that in the vaginal mucosa, phagocytosis of aminoglycoside-containing epithelial cells results in TLR3 activation due to the accumulation of aminoglycoside-bound RNA in the endosome.
The specific RNA bound by the aminoglycoside that triggers TLR3 remains unknown. The interaction of aminoglycosides with mitochondrial ribosomal RNA, which is closely related to bacterial ribosomal RNA, is well characterized, and aminoglycosides have also been found to bind mitochondrial ribosomal RNA at multiple . Data were pooled from two independent experiments. Error bars represent s.e.m. and significance was calculated using unpaired t-tests. c, Depo-treated XCR1 DTR mice were treated with 500 ng diphtheria toxin to deplete XCR1 + DC, treated intravaginally with 1 mg neomycin for two days (n = 2-5). Vaginal gene expression measured by qPCR. Error bars represent s.d. and significance was calculated using two-way ANOVA with Holm-Sidak correction for multiple comparisons. *P < 0.05. Exact P values for all comparisons are reported in Supplementary Table 2 .
Articles NATuRe MICRobIoloGy sites 36, 50 . It is possible that mitochondrial rRNA-bound aminoglycosides might activate TLR3 in XCR1 + DCs in the endosome. Our results show that aminoglycoside and Poly(I:C) can synergize to induce increased ISG expression (Supplementary Fig. 13 ). Future studies are needed to identify the manner in which aminoglycosidebound RNA stimulates TLR3.
Our results demonstrate a surprising and broad antiviral effect of the aminoglycoside family of antibiotics, when applied to mucosal surfaces. However, we do not advocate for use of these compounds as antivirals, as aminoglycoside application is expected to cause local dysbiosis of the commensal bacterial community. Understanding the precise mechanism by which aminoglycosides induce TLR3 stimulation will be useful for the future design of novel broad-acting antivirals with no antimicrobicidal activity.
Methods
Mice. C57BL/6 (B6, Charles River Laboratories), B6(Cg)-Ifnar1tm1.2Ees/J (Ifnar1 ) and B6129SF2/J controls were purchased from Jackson Laboratory unless otherwise specified, and subsequently bred and housed at Yale University. Irf3
) (gift from Z. Chen, UTSW) and B6.CgXcr1 tm2(HBEGF/Venus)Ksho (XCR1-DTR) (ref.
29
) have been described previously. C57BL/6 mice carrying functional Mx1 alleles were a gift from P. Staeheli 52 (University Medical Center Freiburg). Mice were maintained in our facility until the ages described. Germ-free Swiss Webster mice were maintained in flexible plastic gnotobiotic isolators with a 12 h light/dark cycle and provided with a standard, autoclaved mouse chow (5K67 LabDiet, Purina) ad libitum and autoclaved water for the duration of the experiment. Germ-free status was monitored by culturebased (aerobic and anaerobic culturing) and culture-independent methods (16S-targeted PCR). All procedures used in this study complied with federal and institutional policies of the Yale Animal Care and Use Committee.
Viruses. WT HSV-2 (strain 186syn
+ ) was a gift from D. Knipe (Harvard Medical School). HSV strain was propagated in Vero cells (ATCC CCL-81) as previously described 53 . The highly virulent variant of A/PR8 (ref. 17 ) was a gift from P. Staeheli (University Medical Center Freiburg). Influenza virus strain A/PR/8/34 (H1N1) was propagated as previously described 16 . ZIKV Cambodian FSS13025 strain was obtained from the World Reference Center for Emerging Viruses and Arboviruses at University of Texas Medical Branch, Galveston. ZIKV stocks were propagated in C6/36 mosquito cells (Aedes albopictus) (ATCC CRL-1660) as previously described 18 . Cell lines obtained from ATCC were not further authenticated and all cell lines were routinely tested for mycoplasma contamination.
Mouse infections and antibiotic treatment. C57BL/6 mice between 6 and 17 weeks of age were subcutaneously injected with 2 mg Depo-Provera in the neck scruff. Five days after Depo treatment, the mice were vaginally swabbed with a calcium alginate swab (Puritan) to remove vaginal mucus. The swab was wetted in sterile PBS and blotted on sterile paper to get rid of excess liquid before being used. Between 10 and 15 μ l of antibiotic or PBS was delivered into the vaginal cavity using a pipette tip. After 2-6 days of daily antibiotic treatment, mice were infected intravaginally with 2 × 10 3 to 5 × 10 3 p.f.u. HSV-2, 10 6 p.f.u. HSV-1 or 2.5 × 10 5 p.f.u. ZIKV. Infections were carried out 24 h after the last antibiotic treatment. At the time of infection, mice were weighed and subsequently examined at the same time each day to minimize fluctuations in weight due to circadian rhythms.
Vaginal viral titres were collected by swabbing mice and flushing the vaginal cavity with 50 μ l of PBS. Mice were monitored daily for signs of inflammatory pathology scored as follows: 0, no inflammation; 1, genital inflammation; 2, genital lesions and hair loss; 3, hunched posture and ruffled fur; 4, hind-limb paralysis; 5, premoribund. Mice were euthanized before reaching a moribund state. Intranasal influenza infections were conducted as described previously 16 . Briefly, mice were anaesthetized using a mixture of ketamine and xylazine injected i.p. and infected with 500 p.f.u. highly virulent A/PR8 influenza strain. All mouse experiments were carried out with a minimum of three to four mice per treatment group. With the exception of the germ-free mouse infections and experiments with XCR1 DTR mice, all other experiments were repeated independently at least once. These experiments were only conducted once with total n = 5. All mouse experiments were conducted on female mice with the exception of intranasal aminoglycoside treatment and influenza infection experiments, which were conducted with both male and female mice. Mice in each experiment were age-matched within the timeframe of a week and cage mates were randomly distributed into different treatment groups to control for cage effects. All mouse experiments were conducted with a minimum of four to five mice for infection experiments and a minimum of three mice for gene expression experiments. All animal procedures were performed in compliance with Yale Institutional Animal Care and Use Committee protocols.
Antibiotic treatment. The antibiotic cocktail consisted of 0.5 mg ampicillin sodium salt, vancomycin hydrochloride and neomycin sulfate and 0.01 mg metronidazole in a 15 μ l volume. For subsequent experiments using neomycin alone, mice were treated with 1 mg in a volume of 10 μ l. For intranasal treatment, mice were anaesthetized by injecting a mixture of ketamine and xylazine i.p. and 20 μ l of antibiotic was administered dropwise into the nasal cavity using a pipette tip. All antibiotics with the exception of neamine A were obtained from SigmaAldrich. Neamine A was obtained from Carbosynth.
Microarray analysis. Mice were treated daily with neomycin (1 mg per day) or PBS for six days and then euthanized, and vaginal tissue was collected. RNA was extracted from the vaginal tissues using an RNeasy extraction kit (Qiagen) and hybridized onto MouseWG-6 v2 Expression arrays (Illumina) at the Yale Center for Genome Analysis. Microarray data were visualized using the ggplot2 (v. Flow cytometry analysis. Single-cell populations were isolated from vaginal tissue as previously described 53 . Briefly, vaginal tissue was minced into small pieces and digested first with Dispase II for 15 min and subsequently with a combination of DNase I (0.045 mg ml −1 ) and collagenase (2 mg ml −1 ) for 30 min. All digestions were carried out in a 37 °C shaking water bath. All enzymes were obtained from Sigma-Aldrich. Cells were spun down and dead cells excluded using a live/dead stain (Molecular Probes, Thermo Fisher), then stained with appropriate antibodies, fixed with 1% paraformaldehyde (Electron Microscopy Sciences) and run through an LSR II (BD Biosciences) equipped with a UV laser. FlowJo software v.9.8.2 (Tree Star) was used to visualize and analyse cytometry data. Cells populations were analysed as shown in the gating scheme ( Supplementary Fig. 14) .
Antibodies. The following antibodies were used for this study, all purchased from Biolegend unless specified otherwise: CD45(104), CD3ε (145-2C11), CD11c (HL3, BD Biosciences), CD11b (M1/70), CD103 (2E7) XCR1 (ZET), SIRPα (P84), Gr1 (RB6-8C5, BD Biosciences), NK1.1(PK136), MHC class II I-A/I-E (M5/114.152) and CD19 (6D5).
Human monocyte isolation and infection. Peripheral blood mononuclear cells were obtained from the New York Blood Bank Center and monocytes were isolated using a negative selection kit (Stemcell Technologies). Monocytes were treated with Poly(I:C) (Sigma) or aminoglycosides at 2 μ g ml −1 and 2 mg ml −1 , respectively for 6 h. Cells were washed once and infected with influenza A virus strain A/PR/8/34 (H1N1) at a multiplicity of infection of 2. Cells were incubated with the virus for 1 h in PBS containing 0.1% BSA . Cells were then washed once and incubated in DMEM containing 10% FBS, pen/strep, sodium pyruvate and Hepes. RNA was isolated using an RNeasy extraction kit (Qiagen) and viral RNA quantified using primers against influenza A PR8 polymerase A (FP:CGGTCCAAATTCCTGCTGAT; RP: CATTGGGTTCCTTCCATCCA).
Viral titre.
Vaginal washes from HSV-2 infected mice were collected in 50 μ l PBS and saved in 950 μ l PBS supplemented with 1% FBS, 10 mg ml −1 glucose NATuRe MICRobIoloGy 0.5 μ M MgCl 2 and 0.9 μ M CaCl 2 . Washes were added in serial dilutions to a confluent monolayer of Vero cells and plaques visualized via crystal violet staining. The ZIKV genome was quantified by qRT-PCR as previously described 18 . Briefly, cDNA prepared from vaginal washes was compared against a standard curve composed of purified ZIKV viral genomes. Primers against NS5 (F: GGCCACGAGTCTGTACCAAA; R: AGCTTCACTGCAGTCTTCC) were used to measure ZIKV RNA.
In vitro treatments. Single-cell splenocytes were plated at a density of 5 × 10 6 cells per ml, isolated and treated with kasugamycin (2 mg ml −1 or 0.02 mg ml
) and Poly(I:C) (high molecular weight, Invivogen; 2 μ g ml −1 or 0.02 μ g ml
) for 6 h. Mixtures of Poly(I:C) and kasugamycin were incubated together for 30 min at 37 °C before addition to cells. For Supplementary Fig. 13 , splenocytes were treated for 12 h, washed five times, stained with cell trace violet (Thermo Fisher) and incubated with splenic DCs isolated using a PanDC separation kit (Stemcell Technologies). After 6 h incubation, cell trace violet dim and negative cells were sorted using a FACSAria (BD) into lysis buffer (Qiagen) for RNA extraction. All in vitro experiments were conducted with a minimum of three replicates and repeated twice.
Statistics. Gene expression data were analysed using unpaired t-tests, assuming unequal standard deviation and correcting for multiple comparisons using the Holm-Sidak correction unless otherwise specified. Graphs depicting disease scores were analysed using two-way ANOVA with Holm-Sidak correction for multiple comparisons. Graphs depicting viral titres across a time course of infection were analysed using two-way ANOVA with no correction for multiple comparisons (Fisher's LSD) unless otherwise specified. Survival curves were analysed using the log-rank (Mantel-Cox) test. Data from pooled experiments contained a control group within each experiment. P values not reported in the figures themselves are provided in Supplementary Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
All mouse experiments were carried out with a minimum of 3-4 mice per treatment group. With the exception of the germ-free mouse infections and experiments with XCR1DTR mice, all other experiments were independently repeated at least once. These experiments were only conducted once with a total n=5. For all in-vitro experiment, each experiment was conducted with thee technical replicates and each experiment was repeated at least twice ensuring 2 biological replicates).
Data exclusions
Describe any data exclusions.
No animals were excluded from analysis with the exception of a single PBS-treated control animal in Supplementary Figure 2 . Vaginal gene expression in this animal was a consistent outlier by Gibbs outlier test in 6/8 genes tested leading us to to exclude the animal from gene expression analysis. Criteria were not pre-established as we did not expect to see this degree of variation and it was not observed for any of the other animals in the experiments listed (>100 animals).
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All animal infection experiments and gene expression experiments were repeated at least twice with the sole exception of experiments with XCR1-DTR mice which was only conducted once. All in-vitro experiments were conducted at least twice with three technical replicates each time. For each figure, the legend describes whether the data presented is pooled from 2-3 independent experiments or if representative, how many times it was repeated.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Female mice of a specific genotypes were randomly allocated into treatment and control groups to avoid cage effects. This allocation took place after depo-provera and before the treatment or infection timeline. After infection experiments were not blinded.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The histopathologist consulted for data presented in Supplementary Figure 11a was blinded as to group allocation -H&E stained slides from treatment and control groups were randomly numbered by the investigator and not disclosed till after the report was generated.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
There are no unique materials used in this study.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The following antibodies were used for this study for flow cytometry analyses. All antibodies purchased from Biolegend unless specified otherwise: CD45 (104) c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines were tested for mycoplasma contamination every 6-12 months.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
N/A
